Model Portfolio Email Alerts

Posted on | by Craig

We’ve changed how our Model Portfolio emails are sent out to subscribers. From now on, all model changes will be included in our daily blog post at 11am, while your custom selections, will be emailed to you at 8am.

To customize the models you’re interested in tracking, use the toggle option in the toolbar of the Model Portfolio window in our Members Area. Select the model you’re interested in, (or no longer interested in) and press the grey or green envelope.

Grey means that we will not email you about changes to that model. Green means that we will. Remember, this setting is unique to each Model and our alerts are sent out each morning at around 8 am.

Cure ETF – Buy

Posted on | by Leon Hinde

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.

Sunrise Energy – Speculative Buy

Posted on | by Leon Hinde

Sunrise Energy Metals is progressing its world-class Sunrise Battery Materials Complex in New South Wales.

The Sunrise Project is one of the largest and most cobalt-rich nickel laterite deposits in the world and is development-ready, with all key permits and approvals in place.  Sunrise is also one of the largest and highest grade scandium deposits globally.

The company requires a funding solution, (or JV partnership), to continue the development of the Sunrise project and we expect to hear news on this front within 6 – 9 months.

SRL is a high risk, high reward speculative opportunity, however, we feel the risks are skewed to the upside and traders may wish to run a stop loss on a break below $1.60

Cure ETF – Buy

Posted on | by Leon Hinde

CURE:AXW is under Algo Engine buy conditions and the current pullback provides another buying opportunity.

ETFS S&P Biotech ETF (ASX Code: CURE) offers investors exposure to U.S. biotechnology companies. These companies are engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

.